BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
BMO Capital Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $37
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Express News | BridgeBio Pharma Inc - Topline Data Readout From Interim Analysis Expected in 2025
Express News | BridgeBio Completes Enrollment of Fortify, Phase 3 Registrational Study of Bbp-418 in Limb-Girdle Muscular Dystrophy Type 2I/R9 (Lgmd2I/R9)
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43